Menu Back toSession-3-The-Future-is-Now

DIA/FDA Biostatistics Industry and Regulator Forum

Session 7: The Future is Now

Session Chair(s)

Rima  Izem, PhD

Rima Izem, PhD

  • Lead Mathematical Statistician,Div.of BiometricsVII,Office of Biostatistics,OTS
  • FDA, United States
Pandurang M Kulkarni, PhD

Pandurang M Kulkarni, PhD

  • Vice President, Global Biometrics & Advanced Analytics
  • Eli Lilly and Company, United States
Artificial intelligence and machine learning have achieved great successes in many fields such as text mining, image, and voice recognition and are changing our lives. The use of these methods could revolutionize pharma and healthcare. Statisticians are in a great position to provide leadership in this area by (a) ensuring methodologies are fit for purpose, (b) developing reliable training sets, and (c) accounting for variability and uncertainty associated with multiple data sources. In this session, key opinion leaders from industry, academia, and regulatory will share their thoughts and visions, and their journey on using machine learning and artificial intelligence in healthcare industry.
Learning Objective : At the conclusion of this session, participants should be able to:
  • Describe an overview of machine learning methods
  • Identify current applications of machine learning methods in public health
  • Discuss potential future uses of machine learning methods in public health


Haoda  Fu

The Future is Now. But Where Should We Focus?

Haoda Fu

  • Senior Research Scientist
  • Eli Lilly and Company, United States
Sherri  Rose


Sherri Rose

  • Associate Professor of Biostatistics
  • Harvard Medical School | Department of Health Care Policy, United States
Henry "Skip" Francis, MD


Henry "Skip" Francis, MD

  • Director for Data Mining and Informatics Evaluation and Research, OTS, CDER
  • FDA, United States